RESUMEN
BACKGROUND: There are a few case reports in literature that isotretinoin treatment may alter sleep architecture. Also studies in mice suggest a role of retinoids in the contribution of delta oscillations to the sleep electroencephalography. OBJECTIVES: The aim of this study was to investigate the effect of isotretinoin treatment on sleep architecture using polysomnography (PSG). PATIENTS AND METHODS: Twelve severe acne vulgaris patients without any psychiatric and sleep disorders were treated with 0.5 mg/kg of isotretinoin. Clinician-administered acne questionnaire, psychiatric examination, Epworth sleepiness scale and PSG recordings were performed after the first month of treatment. RESULTS: Sleep efficiency was increased from 83.5% (62.8-89.0%, quartiles) to 89.5% (81.5-93.5%, quartiles; P = 0.036) and sleep latency decreased from 18.0 min (11.1-36.3, quartiles) to 15.5 min (9.3-19.0, quartiles; P = 0.023) following 1-month isotretinoin treatment. There were no significant changes in other sleep parameters of PSG and scores of Epworth sleepiness scale. CONCLUSIONS: This study suggests that isotretinoin treatment slightly improves night-time sleep without any effects on sleep stages and daytime sleepiness.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Fármacos Dermatológicos/uso terapéutico , Isotretinoína/uso terapéutico , Sueño/efectos de los fármacos , Adolescente , Adulto , Fármacos Dermatológicos/efectos adversos , Femenino , Humanos , Isotretinoína/efectos adversos , Masculino , Proyectos Piloto , Polisomnografía , Encuestas y Cuestionarios , Adulto JovenRESUMEN
BACKGROUND: Growth hormone (GH) may play an important role in the content and appearance of the skin. Dry, thin and pale skin has been described in hypopituitarism. Sheehan's syndrome is characterized by anterior pituitary dysfunction due to postpartum pituitary necrosis and GH is one of the hormones lost first. OBJECTIVE: The aim of this study was to examine the hydration of the skin of patients with Sheehan's syndrome using measurements of capacitance, sebum content, transepidermal water loss, pH and temperature. The data were compared with those of control subjects. METHODS: A total of 21 patients with Sheehan's syndrome and 20 women as control subjects were included in this blinded prospective study. Hormone deficiencies other than GH had been adequately replaced. The diagnosis of GH deficiency (GHD) was established by the insulin tolerance test (ITT). Skin properties were measured by non-invasive and well-established methods. RESULTS: The skin capacitance had decreased on the forehead and forearm and sebum content had decreased on the forehead of patients with Sheehan's syndrome when compared with control subjects. The pH, temperature and average transepidermal water loss (TEWL) of the skin of the patients were not statistically different from the controls. CONCLUSION: GHD results in a decrease in skin capacitance and sebum content indicating that GH and/or insulin-like growth factor-I (IGF-I) have an important role in skin function.
Asunto(s)
Hormona de Crecimiento Humana/deficiencia , Hipopituitarismo/complicaciones , Enfermedades de la Piel/etiología , Adulto , Anciano , Capacidad Eléctrica , Femenino , Antebrazo , Frente , Humanos , Concentración de Iones de Hidrógeno , Masculino , Persona de Mediana Edad , Temperatura CutáneaRESUMEN
BACKGROUND: Pruritus is a common problem in continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis patients. There are few studies on the clinical characteristics of uremic itch, the cause of which is still unknown. OBJECTIVES: The aim of this study was to define the prevalence and clinical characteristics of pruritus in CAPD and haemodialysis patients. METHODS: A questionnaire was used to evaluate pruritus in 52 CAPD and 289 haemodialysis patients in two dialysis units. The relationship of various factors and medical parameters to itch was examined. RESULTS: Of the 341 patients, 177 (51.9%) had pruritus at the time of examination, 97 (28.4%) had pruritus in the past. Pruritus was present in 145 (50.2%) of the haemodialysis patients and 32 (61.5%) of the CAPD patients. Men, patients with liver disease, and patients with pruritus before starting dialysis treatment were more likely to have uremic pruritus. CONCLUSIONS: This study showed us that uremic pruritus was observed more in men than women. The high prevalence of uremic pruritus in our study does not support the decrease of pruritus due to an improvement in the management of dialysis patients.
Asunto(s)
Prurito/epidemiología , Prurito/etiología , Uremia/complicaciones , Uremia/epidemiología , Actividades Cotidianas , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Diálisis Peritoneal Ambulatoria Continua , Prevalencia , Prurito/patología , Prurito/psicología , Análisis de Regresión , Diálisis Renal , Encuestas y CuestionariosAsunto(s)
Poroqueratosis/diagnóstico , Adulto , Diagnóstico Diferencial , Cara/patología , Femenino , Humanos , Poroqueratosis/patologíaAsunto(s)
Lupus Eritematoso Cutáneo/complicaciones , Lupus Eritematoso Cutáneo/diagnóstico , Psoriasis/complicaciones , Psoriasis/diagnóstico , Adulto , Biopsia con Aguja , Terapia Combinada , Técnica del Anticuerpo Fluorescente Indirecta , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Lupus Eritematoso Cutáneo/terapia , Masculino , Psoriasis/terapia , Medición de Riesgo , Índice de Severidad de la EnfermedadAsunto(s)
Colecistectomía/efectos adversos , Piodermia Gangrenosa/diagnóstico , Infección de la Herida Quirúrgica/diagnóstico , Antibacterianos/administración & dosificación , Colecistectomía/métodos , Colelitiasis/cirugía , Ciclosporina/administración & dosificación , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Piodermia Gangrenosa/etiología , Piodermia Gangrenosa/terapia , Medición de Riesgo , Infección de la Herida Quirúrgica/etiología , Resultado del TratamientoRESUMEN
BACKGROUND: T-cell activation has been implicated in the pathogenesis of psoriasis; adenosine deaminase (ADA) activity has been considered as a marker of T-cell activation. The antithyroid drug propylthiouracil (PTU) has recently been shown to have beneficial effects on psoriatic lesions, probably by acting on the immune system. OBJECTIVES: To investigate whether ADA activity may be related to psoriasis and whether oral PTU affects ADA activity and gives clinical improvement in psoriatic patients. METHODS: ADA activities were measured in plasma, erythrocyte and tissue samples of patients with psoriasis before and after 2 months of treatment with either PTU 100 mg three times daily or PTU plus thyroxine 25 microg once daily (to prevent possible hypothyroidism, which may be induced by PTU) as well as in healthy controls. The severity of the disease was evaluated before and after treatment according to Psoriasis Area and Severity Index (PASI) scores. Routine analyses and thyroid function tests were also carried out during the study. RESULTS: All patients showed significant clinical improvement in their lesions and decreased PASI scores after the treatments. Elevated baseline ADA activities in skin and plasma were found to be lower, and decreased baseline erythrocyte ADA was higher, after the treatments in all patients, and they were not different from control values. Although thyroid function tests were not affected by the treatments, serum thyroid-stimulating hormone levels were found to be higher after the treatments, and there was a larger increase in patients treated with PTU alone. However, none of the patients had clinical hypothyroidism or cytopenia. CONCLUSIONS: ADA activity may be clinically useful for indicating T-cell activation in psoriasis. Because of its antiproliferative and immunomodulatory effects, antioxidant potential and low toxicity, PTU may be an effective agent in the treatment of psoriasis.
Asunto(s)
Adenosina Desaminasa/efectos de los fármacos , Fármacos Dermatológicos/farmacología , Propiltiouracilo/farmacología , Psoriasis/enzimología , Glándula Tiroides/efectos de los fármacos , Adenosina Desaminasa/metabolismo , Adolescente , Adulto , Anciano , Biomarcadores , Fármacos Dermatológicos/uso terapéutico , Eritrocitos/enzimología , Femenino , Humanos , Hipotiroidismo/prevención & control , Masculino , Persona de Mediana Edad , Propiltiouracilo/uso terapéutico , Psoriasis/tratamiento farmacológico , Psoriasis/fisiopatología , Índice de Severidad de la Enfermedad , Glándula Tiroides/fisiopatología , Tirotropina/sangre , Tiroxina/sangre , Tiroxina/uso terapéutico , Triyodotironina/sangreRESUMEN
BACKGROUND: A higher prevalence of Helicobacter pylori infection in rosacea patients than in healthy controls has been reported. OBJECTIVE: The aim of this study was to investigate the effect of H. pylori eradication therapy in patients with rosacea. METHODS: Twenty-five rosacea patients and 87 age- and sex-matched healthy controls were included in this study. We detected IgG and IgA antibodies against H. pylori in both groups. An upper gastrointestinal endoscopy and a rapid urease test were performed on the 13 patients with rosacea who accepted this procedure. Amoxicillin 500 mg 3 times daily, metronidazole 500 mg 3 times daily, and bismuth subcitrate 300 mg 4 times daily were administered to patients positive for H. pylori. The severity of rosacea was scored before and after treatment. RESULTS: There was no statistical difference in seropositivity in either group. In H. pylori-positive rosacea patients there was a significant decrease in the severity of rosacea at the end of the treatment as compared with the initial scores. CONCLUSION: Our findings suggest that H. pylori may be involved in rosacea and that eradication treatment may be beneficial.
Asunto(s)
Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/epidemiología , Rosácea/epidemiología , Rosácea/microbiología , Adulto , Anciano , Amoxicilina/uso terapéutico , Antiácidos/uso terapéutico , Antibacterianos/uso terapéutico , Anticuerpos Antibacterianos/sangre , Bismuto/uso terapéutico , Femenino , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/inmunología , Helicobacter pylori/inmunología , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Compuestos Organometálicos/uso terapéutico , Rosácea/complicaciones , Rosácea/inmunología , Resultado del TratamientoAsunto(s)
Albuminuria/orina , Psoriasis/orina , Adolescente , Adulto , Albuminuria/fisiopatología , Presión Sanguínea/fisiología , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/fisiopatología , Diabetes Mellitus Tipo 2/orina , Diástole , Femenino , Humanos , Masculino , Persona de Mediana Edad , Psoriasis/patologíaRESUMEN
Three hundred eighty three serum samples obtained from various patient groups and health care personnel were tested for HBsAg, Anti-HCV and Anti-HDV by ELISA technique. Anti-HCV antibodies were found 32.4% of chronic haemodialysis patients, 23% of the patients with chronic viral hepatitis and cirrhosis, 8.3% of health care personnel and less frequently detected in other groups. Anti-HDV antibodies were found 23% of the patients with chronic viral hepatitis and cirrhosis, 2.7% of blood donors, 8.1% of chronic haemodialysis patients and 1.3% of the patients who have malignancy. Anti-HDV antibodies were not detected in other groups.